PROF (Profound Medical) 1-Year Sharpe Ratio: 0.38 (As of Jul. 07, 2026)


PROF Profound Medical Corp PROF
73 GF Score
Price $7.21
GF Value $14.28
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Profound Medical 1-Year Sharpe Ratio?

Profound Medical PROF -1.77% 73 1-Year Sharpe Ratio is 0.38 as of Jul. 07, 2026. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-07), Profound Medical's 1-Year Sharpe Ratio is 0.38.

Profound Medical  (NAS:PROF) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Profound Medical 1-Year Sharpe Ratio Related Terms

PROF vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, Profound Medical's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Profound Medical 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Profound Medical's 1-Year Sharpe Ratio falls into.


PROF
73GF Score
Profound Medical Corp PROF
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Profound Medical 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.38 mean?
Profound Medical (PROF) has a 1-Year Sharpe Ratio of 0.38 as of Jul. 07, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Profound Medical and its competitors.
Is Profound Medical's 1-Year Sharpe Ratio too high?
Profound Medical's current 1-Year Sharpe Ratio is 0.38. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's 1-Year Sharpe Ratio compare to ABT and SYK?
Profound Medical's 1-Year Sharpe Ratio of 0.38 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Profound Medical and its competitors. Profound Medical's current 1-Year Sharpe Ratio is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.21 — trading 49.5% below its estimated fair value. The current 1-Year Sharpe Ratio is 0.38. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Profound Medical (PROF), the current 1-Year Sharpe Ratio is 0.38 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Profound Medical (PROF) Overvalued in 2026?

Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued. The current stock price of $7.21 is trading 49.5% below its estimated GF Value™ of $14.28. GuruFocus considers Profound Medical to be Possible Value Trap.

Key valuation signals for PROF:

  • 1-Year Sharpe Ratio: 0.38
  • GF Value™: $14.28 vs. price of $7.21 (49.5% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Profound Medical Business Description

Other Exchanges PRN:Canada
Address 2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score

Get the complete analysis for PROF

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.21
Price
$14.28
GF Value